Huibin Yue

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1

Carl D. Regillo, David M. Brown, Prema Abraham et al. · American Journal of Ophthalmology · 2008 · 859 citations

Ocular Disease, Ophthalmology, Experimental Ophthalmology +4

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2

Prema Abraham, Huibin Yue, Laura Wilson · American Journal of Ophthalmology · 2010 · 443 citations

Ocular Disease, Ophthalmology, Experimental Ophthalmology +5

Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial

Marcia S. Brose, Maria E. Cabanillas, Ezra E.W. Cohen et al. · The Lancet Oncology · 2016 · 376 citations · Full text

Oncology, Radioactive Iodine, Thyroid Disease +4

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC

Aleksandar Sekulić, Michael R. Migden, Karl D. Lewis et al. · Journal of the American Academy of Dermatology · 2015 · 207 citations

Tumor Biology, Medicine, Cancer Management +8

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors

John H. Strickler, Colin D. Weekes, John Nemunaitis et al. · Journal of Clinical Oncology · 2018 · 135 citations · Full text